Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Steven P Marso^{1,2,3,4,5,6,7,8,9,10}, Gilbert H Daniels^{1,2,3,4,5,6,7,8,9,10}, Kirstine Brown-Frandsen^{1,2,3,4,5,6,7,8,9,10}, Peter Kristensen^{1,2,3,4,5,6,7,8,9,10}, Johannes F E Mann^{1,2,3,4,5,6,7,8,9,10}, Michael A Nauck^{1,2,3,4,5,6,7,8,9,10}, Steven E Nissen^{1,2,3,4,5,6,7,8,9,10}, Stuart Pocock^{1,2,3,4,5,6,7,8,9,10}, Neil R Poulter^{1,2,3,4,5,6,7,8,9,10}, Lasse S Ravn^{1,2,3,4,5,6,7,8,9,10}, William M Steinberg^{1,2,3,4,5,6,7,8,9,10}, Mette Stockner^{1,2,3,4,5,6,7,8,9,10}, Bernard Zinman^{1,2,3,4,5,6,7,8,9,10}, Richard M Bergenstal^{1,2,3,4,5,6,7,8,9,10}, John B Buse^{1,2,3,4,5,6,7,8,9,10}

1. From the University of Texas Southwestern Medical Center, Dallas (S.P.M.)
2. Massachusetts General Hospital, Boston (G.H.D.)
3. Novo Nordisk, Bagsvaerd, Denmark (K.B.-F., P.K., L.S.R., M.S.)
4. Friedrich Alexander University of Erlangen, Erlangen (J.F.E.M.), and St. Josef Hospital, Ruhr University, Bochum (M.A.N.) - both in Germany
5. Cleveland Clinic, Cleveland (S.E.N.)
6. London School of Hygiene and Tropical Medicine Medical Statistics Unit (S.P.) and Imperial College London (N.R.P.), London
7. George Washington University Medical Center, Washington, DC (W.M.S.)
8. Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto (B.Z.)
9. International Diabetes Center at Park Nicollet, Minneapolis (R.M.B.)
10. and the University of North Carolina School of Medicine, Chapel Hill (J.B.B.).

The New England journal of medicine 2016 Vol. 375 · Issue 4 · pp. 311-22

PMID 27295427 DOI 10.1056/nejmoa1603827